Disease & disorder
short stature due to primary acid-labile subunit deficiency
MONDO:0014420
Short stature due to primary acid-labile subunit (ALS) deficiency is characterized by moderate postnatal growth deficit, markedly low circulating levels of insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP-3), and hyperinsulinemia, in the absence of growth hormone (GH) deficiency or GH insensitivity.
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
Loading mapped interventions…
MONDO disease family
Loading verified ontology relationships…
Recruiting studies by city
Loading research-site locations…
Trial status
Loading…
Trial phase
Loading…
Study start year
Loading…
Investigated drug interventions
Loading…
Background context
short stature due to primary acid-labile subunit deficiency
Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.Drugs being studied
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.